<DOC>
	<DOCNO>NCT01109121</DOCNO>
	<brief_summary>This Phase 2 study multicenter , double-blind , randomize , active-comparator study evaluate safety efficacy tranilast combination allopurinol patient hyperuricemia moderate severe gout .</brief_summary>
	<brief_title>Tranilast Plus Allopurinol Patients With Moderate Severe Gout ( TAnGO )</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Tranilast</mesh_term>
	<criteria>Male female , age 18 80 Severe gout , demonstrate 3 gout flare previous 12 month , presence least one gout tophus gouty arthritis Hyperuricemia sUA â‰¥8.0 mg/dL Pregnant nursing Known hypersensitivity component tranilast allopurinol Known history xanthinuria kidney stone Use investigational drug within 30 day Presence , history , cancer exception completely excise , nonmetastatic squamous cell basal cell carcinoma skin Subject planning likely require surgical procedure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Moderate severe gout</keyword>
	<keyword>Hyperuricemia</keyword>
</DOC>